The Problem with Copay Adjustment and Alternate Funding Programs

patient-worried-healthcare-bill

Payers’ use of copay adjustment programs has exploded over the past few years, and interest in them remains high. In addition, payers are now looking to bring down their drug spend by adopting newer strategies offered by companies with alternate funding programs. While many manufacturers are pushing back against these copay adjustment and specialty carve-out […]

What’s Ahead for Market Access in 2023?

looking-at-market-access-2023

Despite the challenges of the pandemic, the pharma industry has enjoyed steady growth during the past two years, which is expected to continue in 2023. The global pharmaceutical market is forecast to expand at a CAGR of 5.7% between now and 2028. Hundreds of products are currently awaiting FDA approval, and new modalities, including cell […]

What the Inflation Reduction Act Means for Manufacturers and Health Plans

syringe-wrapped-in-dollar-inflation-reduction

Given the spotlight that COVID-19 has shone on the glaring holes within the U.S. healthcare system, it’s not surprising that the current Biden administration has placed considerable importance on addressing key issues head-on. The focus on solving these issues has manifested as the Inflation Reduction Act (IRA), which passed along party lines in the Senate […]

What Manufacturers Need to Know About Alternative Payment Models

creative-business-people-meeting-at-office

Much has been said about healthcare’s shift from a fee-for-service model to a value-based care (VBC) model—and for good reason. With 50% of clinical interventions resulting in unknown effectiveness, and 20-40% of health expenditure wasted on unproven or unnecessary treatments, VBC models can help reduce costs and inefficiencies for patients, providers and manufacturers. Yet while […]

Payers Are Using NDC Mandates, but Are They Doing Enough?

female-analyst-at-her-desk-works-on-a-laptop-showing-statistics-graphs-and-charts

The drug development pipeline is dominated by specialty therapies, more and more of which are being managed under the medical benefit. Therefore, payers will increasingly need to manage those drugs themselves, given that the PBMs they’d normally rely on don’t process these sorts of claims. As a result, payers are looking to better manage medical […]

Stay In Touch

Be the first to know about new arrivals and promotions

Upcoming Webinar: Achieving Your Uptake Goals